中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 中国临床肿瘤学会肿瘤心脏病学专家委员会. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148
引用本文: 中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 中国临床肿瘤学会肿瘤心脏病学专家委员会. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148
shu
Society of Integrative Cardio-Oncology China Anti-Cancer Association, The Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardiovascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Docotor Association, The Chinese Society of Clinical Oncology Expert Committee on Cardio-Oncology. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148
Citation: Society of Integrative Cardio-Oncology China Anti-Cancer Association, The Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardiovascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Docotor Association, The Chinese Society of Clinical Oncology Expert Committee on Cardio-Oncology. Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(20): 1027-1038. DOI: 10.3969/j.issn.1000-8179.2020.20.148
shu

免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版)

Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)

    摘要
  • 摘要: 免疫检查点抑制剂(immune checkpoint inhibitors，ICIs)为肿瘤患者带来显著生存获益的同时，其致命性的药物相关心肌炎并发症成为临床中的新挑战。本共识总结ICIs相关心肌炎的流行病学、病理特点、临床特点、诊断与鉴别诊断、临床分型和对应管理方案，提出主动监测策略(proactive monitoring strategy，PMS)以发现早期心肌损伤，为ICIs相关心肌炎的监测和管理提供指导意见和建议。

     

    Abstract: While immune checkpoint inhibitors (ICIs) confer significant survival benefits in patients with cancer, drug-related myocarditis, a fatal complication, has become a new clinical challenge. This consensus statement summarizes the data on the epidemiology, pathological characteristics, clinical features, diagnosis and differential diagnosis, clinical classification, and treatment of ICI-related myocarditis, with a special focus on proactive monitoring strategies for detecting early myocardial injury. This consensus provides guidance and suggestions for the surveillance and management of ICI-related myocarditis.

     

    • HTML全文
    • 参考文献(68)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回